These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22134384)

  • 1. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis.
    Marchesi C; Dentali F; Nicolini E; Maresca AM; Tayebjee MH; Franz M; Guasti L; Venco A; Schiffrin EL; Lip GY; Grandi AM
    J Hypertens; 2012 Jan; 30(1):3-16. PubMed ID: 22134384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating matrix metalloproteinases and their inhibitors in hypertension.
    Fontana V; Silva PS; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2012 Apr; 413(7-8):656-62. PubMed ID: 22245508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart.
    Vianello A; Caponi L; Franzoni F; Galetta F; Rossi M; Taddei M; Malvaldi G; Pietrini P; Santoro G
    Clin Sci (Lond); 2009 Jul; 117(4):157-64. PubMed ID: 19196241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target.
    Fontana V; Silva PS; Belo VA; Antonio RC; Ceron CS; Biagi C; Gerlach RF; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):130-7. PubMed ID: 21401887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis.
    Noji Y; Kajinami K; Kawashiri MA; Todo Y; Horita T; Nohara A; Higashikata T; Inazu A; Koizumi J; Takegoshi T; Mabuchi H
    Clin Chem Lab Med; 2001 May; 39(5):380-4. PubMed ID: 11434385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects.
    Saglam M; Karakaya O; Esen AM; Barutcu I; Dogan S; Karavelioglu Y; Karapinar H; Akgun T; Esen O; Ozdemir N; Turkmen S; Kaymaz C
    Tohoku J Exp Med; 2006 Feb; 208(2):117-22. PubMed ID: 16434834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs and aging and lifelong exercise adaptations in ventricular and arterial stiffness.
    Carrick-Ranson G; Spinale FG; Bhella PS; Sarma S; Shibata S; Fujimoto N; Hastings JL; Levine BD
    Exp Gerontol; 2019 Aug; 123():36-44. PubMed ID: 31095969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors.
    Latronico T; Mascia C; Pati I; Zuccala P; Mengoni F; Marocco R; Tieghi T; Belvisi V; Lichtner M; Vullo V; Mastroianni CM; Liuzzi GM
    Int J Mol Sci; 2016 Mar; 17(4):455. PubMed ID: 27023536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
    Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
    J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension.
    Fontana V; Silva PS; Izidoro-Toledo TC; Biagi C; Oliveira EB; Gerlach RF; Tanus-Santos JE
    Cardiovasc Drugs Ther; 2012 Dec; 26(6):511-9. PubMed ID: 23085896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of MMPs and TIMPs With the Occurrence of Atrial Fibrillation: A Systematic Review and Meta-analysis.
    Liu Y; Xu B; Wu N; Xiang Y; Wu L; Zhang M; Wang J; Chen X; Li Y; Zhong L
    Can J Cardiol; 2016 Jun; 32(6):803-13. PubMed ID: 26907578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy.
    Essa EM; Zile MR; Stroud RE; Rice A; Gumina RJ; Leier CV; Spinale FG
    J Card Fail; 2012 Jun; 18(6):487-92. PubMed ID: 22633307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure.
    Täger T; Wiebalck C; Fröhlich H; Corletto A; Katus HA; Frankenstein L
    Clin Res Cardiol; 2017 Dec; 106(12):974-985. PubMed ID: 28779229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
    Webb CS; Bonnema DD; Ahmed SH; Leonardi AH; McClure CD; Clark LL; Stroud RE; Corn WC; Finklea L; Zile MR; Spinale FG
    Circulation; 2006 Sep; 114(10):1020-7. PubMed ID: 16923753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling.
    Wei Y; Cui C; Lainscak M; Zhang X; Li J; Huang J; Zhang H; Zheng Z; Hu S
    J Cell Mol Med; 2011 Apr; 15(4):773-82. PubMed ID: 20219015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
    Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
    J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.
    Tayebjee MH; Nadar SK; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):770-4. PubMed ID: 15363818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.